Compare TUYA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | MGTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2018 |
| Metric | TUYA | MGTX |
|---|---|---|
| Price | $1.67 | $9.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $3.17 | ★ $27.75 |
| AVG Volume (30 Days) | 655.3K | ★ 1.0M |
| Earning Date | 11-23-2026 | 11-12-2026 |
| Dividend Yield | ★ 6.78% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $12.58 | $314.19 |
| Revenue Next Year | $11.55 | N/A |
| P/E Ratio | $27.45 | ★ $7.65 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $1.60 | $6.62 |
| 52 Week High | $2.61 | $15.35 |
| Indicator | TUYA | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 23.75 |
| Support Level | $1.67 | $8.84 |
| Resistance Level | $1.75 | $10.06 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 28.57 | 3.29 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.